Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
68.64 USD | +0.04% | -2.95% | -15.27% |
01/07 | HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study | MT |
01/07 | HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.27% | 8.55TCr | |
+56.86% | 82TCr | |
+43.90% | 64TCr | |
-6.57% | 35TCr | |
+17.32% | 31TCr | |
+9.94% | 30TCr | |
+16.08% | 24TCr | |
+2.29% | 22TCr | |
+13.96% | 22TCr | |
+7.98% | 17TCr |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc., Q4 2023 Earnings Call, Feb 06, 2024